LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Glaukos Corp

Gesloten

SectorGezondheidszorg

82 -0.52

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

80.41

Max

83.02

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.5M

-20M

Verkoop

17M

124M

Winstmarge

-15.837

Werknemers

995

EBITDA

12M

-8.6M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+51.18% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-799M

4.6B

Vorige openingsprijs

82.52

Vorige sluitingsprijs

82

Nieuwssentiment

By Acuity

84%

16%

350 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Glaukos Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2025, 23:01 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sep 2025, 22:48 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sep 2025, 21:59 UTC

Winsten

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sep 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

17 sep 2025, 23:39 UTC

Marktinformatie

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sep 2025, 22:19 UTC

Acquisities, Fusies, Overnames

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sep 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sep 2025, 21:00 UTC

Winsten

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sep 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

17 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sep 2025, 19:07 UTC

Marktinformatie

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sep 2025, 18:43 UTC

Marktinformatie

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sep 2025, 18:38 UTC

Marktinformatie

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sep 2025, 18:20 UTC

Marktinformatie

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sep 2025, 18:14 UTC

Marktinformatie

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sep 2025, 17:59 UTC

Marktinformatie

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sep 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sep 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sep 2025, 16:51 UTC

Winsten

Correct: Exor 1H Net Loss -EUR624M

17 sep 2025, 16:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 16:34 UTC

Marktinformatie

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sep 2025, 16:25 UTC

Winsten

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sep 2025, 16:23 UTC

Winsten

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Vergelijking

Prijswijziging

Glaukos Corp Prognose

Koersdoel

By TipRanks

51.18% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 124.5 USD  51.18%

Hoogste 165 USD

Laagste 92 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Glaukos Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technische score

By Trading Central

87.61 / 93Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

350 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat